VANCOUVER, BC / ACCESSWIRE / July 18, 2024 / After successfully completing Phase II clinical trials for their medication to treat Major Depressive Disorder, ABVC BioPharma Inc. and AiBtl BioPharma Inc. are now embarking on a groundbreaking clinical study focused on Depression in Cancer Patients. This new study will integrate AI-driven solutions to address the significant challenge of depression among cancer patients, a condition that often complicates treatment and adversely affects overall quality of life.
Skye Bioscience uplists to the Nasdaq: The San Diego biotech $SKYE is set to make the move from the OTC markets on Thursday. Earlier this year, it raised a total of about $90 million in private placements. Skye recently completed enrollment in a Phase 2a trial in glaucoma and ocular hypertension, and it plans to start an obesity and chronic kidney disease study in the middle of this year. — Kyle LaHucik
ABVC Entered into a Global Licensing of Vitargus with Licensing Income of $33.5M
ABVC BioPharma Reports Annual 2023 Financials